Inhibition of cADP-ribose formation produces vasodilation in bovine coronary arteries

Hypertension. 2000 Jan;35(1 Pt 2):397-402. doi: 10.1161/01.hyp.35.1.397.

Abstract

cADP-ribose (cADPR) induces the release of Ca(2+) from the intracellular stores of coronary artery smooth muscle cells. However, little is known about the role of cADPR-mediated intracellular Ca(2+) release in the control of vascular tone. The present study examined the effects of nicotinamide, a specific inhibitor of ADP-ribosylcyclase, on the vascular tone of bovine coronary arteries. A bovine coronary artery homogenate stimulated the conversion of nicotinamide guanine dinucleotide into cGDP-ribose, which is a measure of ADP-ribosylcyclase activity. Nicotinamide significantly inhibited the formation of cGDP-ribose in a concentration-dependent manner: at a concentration of 10 mmol/L, it reduced the conversion rate from 3.34+/-0.11 nmol. min(-1). mg(-1) of protein in control cells to 1.42+/-0.11 nmol. min(-1). mg(-1) of protein in treated cells, a 58% reduction. In U46619-precontracted coronary artery rings, nicotinamide produced concentration-dependent relaxation. Complete relaxation with nicotinamide occurred at a dose of 8 mmol/L; the median inhibitory concentration (IC(50)) was 1.7 mmol/L. In the presence of a cell membrane-permeant cADPR antagonist, 8-bromo-cADPR, nicotinamide-induced vasorelaxation was markedly attenuated. Pretreatment of the arterial rings with ryanodine (50 micromol/L) significantly blunted the vasorelaxation response to nicotinamide. However, iloprost- and adenosine-induced vasorelaxation was not altered by 8-bromo-cADPR. Moreover, nicotinamide significantly attenuated KCl- or Bay K8644-induced vasoconstriction by 60% and 70%, respectively. These results suggest that the inhibition of cADPR formation by nicotinamide produces vasorelaxation and blunts KCl- and Bay K8644-induced vasoconstriction in coronary arteries and that the cADPR-mediated Ca(2+) signaling pathway plays a role in the control of vascular tone in coronary circulation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / pharmacology
  • ADP-ribosyl Cyclase
  • Adenosine / pharmacology
  • Adenosine Diphosphate Ribose / analogs & derivatives
  • Adenosine Diphosphate Ribose / biosynthesis*
  • Adenosine Diphosphate Ribose / pharmacology
  • Animals
  • Calcium Channel Agonists / pharmacology
  • Calcium Channels / physiology
  • Cattle
  • Coronary Circulation / physiology
  • Coronary Vessels / chemistry
  • Coronary Vessels / drug effects
  • Coronary Vessels / enzymology*
  • Cyclic ADP-Ribose* / analogs & derivatives*
  • Iloprost / pharmacology
  • Niacinamide / pharmacology
  • Phosphorus-Oxygen Lyases / metabolism
  • Potassium Chloride / pharmacology
  • Ryanodine / pharmacology
  • Vasoconstriction / drug effects
  • Vasodilation / drug effects
  • Vasodilation / physiology*
  • Vasodilator Agents / pharmacology

Substances

  • 7-deaza-8-bromo-cyclic ADP-ribose
  • Calcium Channel Agonists
  • Calcium Channels
  • Vasodilator Agents
  • Cyclic ADP-Ribose
  • Ryanodine
  • Adenosine Diphosphate Ribose
  • Niacinamide
  • Potassium Chloride
  • 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
  • ADP-ribosyl Cyclase
  • Phosphorus-Oxygen Lyases
  • Iloprost
  • Adenosine